It should be noted that jorunnamycin A at nontoxic concentrations (0.05–0.5 μM) was previously reported to augment the level of BAX, a pro-apoptosis protein in human lung cancer cells [35]; however, the overexpression of BAX was not indicated in CSC-enriched spheroids treated with jorunnamycin A (Figure 10). Here, BAX is linked to lung cancer.